StockData
Kymera Therapeutics, Inc. logo

Kymera Therapeutics, Inc. (KYMR) stock

KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30227% above fair value
$121.13−0.39 (-0.32%)

Close on Nov 18, 2026Market cap $10.34BP/E –Yield –

Kymera Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Kymera Therapeutics's revenue for the twelve months ending Sep 30, 2026 was $102.24M, up 133.8% year over year. For fiscal 2025 it was $39.21M, down 16.7% from the year before. The highest annual figure on record is $78.59M in fiscal 2023.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$39.21M-16.7%
FY2024Dec 31, 2024$47.07M-40.1%
FY2023Dec 31, 2023$78.59M+67.8%
FY2022Dec 31, 2022$46.83M-35.7%
FY2021Dec 31, 2021$72.83M+114.0%
FY2020Dec 31, 2020$34.03M+1060.0%
FY2019Dec 31, 2019$2.93M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$0-100.0%
Q2 FY2026Jun 30, 2026$65.00M+466.4%
Q1 FY2026Mar 31, 2026$34.37M+55.5%
Q4 FY2025Dec 31, 2025$2.87M-61.2%
Q3 FY2025Sep 30, 2025$2.76M-26.1%
Q2 FY2025Jun 30, 2025$11.48M-55.3%
Q1 FY2025Mar 31, 2025$22.10M+114.8%
Q4 FY2024Dec 31, 2024$7.39M-84.6%
Q3 FY2024Sep 30, 2024$3.74M-20.9%
Q2 FY2024Jun 30, 2024$25.65M+55.3%
Q1 FY2024Mar 31, 2024$10.29M+8.7%
Q4 FY2023Dec 31, 2023$47.89M+196.7%
Q3 FY2023Sep 30, 2023$4.73M-50.5%
Q2 FY2023Jun 30, 2023$16.51M+43.4%
Q1 FY2023Mar 31, 2023$9.47M-1.6%
Q4 FY2022Dec 31, 2022$16.14M+5.7%
Q3 FY2022Sep 30, 2022$9.55M-53.0%
Q2 FY2022Jun 30, 2022$11.51M-37.8%
Q1 FY2022Mar 31, 2022$9.62M-48.6%
Q4 FY2021Dec 31, 2021$15.28M+19.5%
Q3 FY2021Sep 30, 2021$20.34M+39.9%
Q2 FY2021Jun 30, 2021$18.52M+463.2%
Q1 FY2021Mar 31, 2021$18.70M+445.6%
Q4 FY2020Dec 31, 2020$12.79M+597.5%
Q3 FY2020Sep 30, 2020$14.53M+1429.8%
Q2 FY2020Jun 30, 2020$3.29M–
Q1 FY2020Mar 31, 2020$3.43M–
Q4 FY2019Dec 31, 2019$1.83M–
Q3 FY2019Sep 30, 2019$950.00K–

More Kymera Therapeutics figures

See a number that looks wrong?